PT-141 Prices

PT-141 (bremelanotide) is a cyclic heptapeptide melanocortin agonist, FDA-approved as Vyleesi (June 2019) for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women.

It works CENTRALLY through brain melanocortin receptors (MC4R/MC3R in the hypothalamus) to act on sexual desire itself, fundamentally different from PDE5 inhibitors (Viagra/Cialis), which act peripherally on blood flow and don't touch desire.

Honest on efficacy: the Phase 3 RECONNECT effect was real but modest, ~25% of treated women hit a meaningful desire increase vs ~17% on placebo. The dominant side effect is nausea (~40%), plus transient blood-pressure elevation.

Approved only for premenopausal women; male use (ED, libido, PDE5 non-responders) is off-label and shows promise but isn't FDA-approved. Not named on WADA's list but plausibly captured under S2.

PeptidePrices safety rating

8/10 · FDA-approved (Vyleesi)

Mechanism

Melanocortin receptor agonist (MC3R, MC4R). Acts centrally in the hypothalamus to stimulate sexual arousal independent of the vascular system. Does not affect blood pressure like PDE5 inhibitors.

Research areas

Sexual dysfunction (male and female); erectile dysfunction; low libido (FDA-approved for HSDD in women); tanning (off-label).

Regulatory / research status

FDA approved (for specific indications)

Half-life

~2.7 hours.

Storage

Lyophilized vial: store at -20°C long-term or 2-8°C short-term, protected from light.

Reported side effects

Nausea (most common), flushing, headache, transient blood pressure increase, spontaneous erections, hyperpigmentation with repeated use.